{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"44","value":"102"},{"groupId":"OG001","spread":"146","value":"191"},{"groupId":"OG002","spread":"64","value":"143"},{"groupId":"OG003","spread":"71","value":"239"},{"groupId":"OG004","spread":"73","value":"284"},{"groupId":"OG005","spread":"222","value":"372"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"11"},{"groupId":"OG005","value":"6"}],"units":"Participants"}],"description":"Plasma samples for pharmacokinetic (PK) analysis were drawn at pre-dose and at 0.5, 1, 2, 4, 8 (±1), 24 (±4) hours after the first dose of panobinostat, as well as prior to the second dose on Course 1 Day 3. The area under the curve (AUC) was estimated using a noncompartmental method and calculated from time of dosing to the last measurable concentration.","dispersionType":"Standard Deviation","groups":[{"description":"Recurrent or progressive DIPG patients received panobinostat orally every other day, 3 times per week at 10 mg/m\\^2/day for three weeks on, one week off (1 course = 28 days) for up to 26 courses in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Stratum 1, Dose Level 1 (10 mg/m^2)"},{"description":"Recurrent or progressive DIPG patients received panobinostat orally every other day, 3 times per week at 16 mg/m\\^2/day for three weeks on, one week off (1 course = 28 days) for up to 26 courses in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"Stratum 1, Dose Level 2 (16 mg/m^2)"},{"description":"Non-progressed DIPG or H3K27M+ thalamic DMG patients received panobinostat orally every other day, 3 times per week at 16 mg/m\\^2/day for every other week (1 course = 28 days) for up to 26 courses in the absence of disease progression or unacceptable toxicity.","id":"OG002","title":"Stratum 2, Dose Level 1 (16 mg/m^2)"},{"description":"Non-progressed DIPG or H3K27M+ thalamic DMG patients received panobinostat orally every other day, 3 times per week at 22 mg/m\\^2/day for every other week (1 course = 28 days) for up to 26 courses in the absence of disease progression or unacceptable toxicity.","id":"OG003","title":"Stratum 2, Dose Level 2 (22 mg/m^2)"},{"description":"Non-progressed DIPG or H3K27M+ thalamic DMG patients received panobinostat orally every other day, 3 times per week at 28 mg/m\\^2/day for every other week (1course = 28 days) for up to 26 courses in the absence of disease progression or unacceptable toxicity.","id":"OG004","title":"Stratum 2, Dose Level 3 (28 mg/m^2)"},{"description":"Non-progressed DIPG or H3K27M+ thalamic DMG patients received panobinostat orally every other day, 3 times per week at 36 mg/m\\^2/day for every other week (1course = 28 days) for up to 26 courses in the absence of disease progression or unacceptable toxicity.","id":"OG005","title":"Stratum 2, Dose Level 4 (36 mg/m^2)"}],"paramType":"MEAN","populationDescription":"Patients who had PK samples collected and had AUC data available were included.","reportingStatus":"POSTED","timeFrame":"Up to day 3","title":"Area Under the Curve (AUC)","type":"PRIMARY","unitOfMeasure":"h*ng/mL"}